Literature DB >> 22453223

The prevalence of microscopic hematuria in women with pelvic organ prolapse.

Dara F Shalom1, Stephanie N Lin, Sarah St Louis, Lawrence R Lind, Harvey A Winkler.   

Abstract

OBJECTIVE: : The objective of the study was to determine the prevalence of microscopic hematuria (MH) in women with pelvic organ prolapse. STUDY
DESIGN: : Data of all patients presenting to a urogynecologic center with pelvic organ prolapse between 2008 and 2010 were reviewed. Microscopic hematuria was defined as 3 or more red blood cells per high-power field on at least 2 urinalysis specimens with negative cultures. Exclusion criteria included age younger than 40 years, presence of gross hematuria, menses, or urologic disease. Statistical analysis was performed using JMP 4.0.4 (SAS Institute, Cary, NC).
RESULTS: : The population consisted of 572 women aged 40 to 96 years. Fifty-five patients (9.6%) met the criteria for MH, and 126 (22%) had 3 or more red blood cells per high-power field on 1 urinalysis. No cases of urologic malignancy were diagnosed on further workup. All patients with microhematuria had cystoceles on examination.
CONCLUSIONS: : Our findings suggest that the prevalence of MH is increased in women with pelvic organ prolapse.

Entities:  

Year:  2011        PMID: 22453223     DOI: 10.1097/SPV.0b013e3182357afb

Source DB:  PubMed          Journal:  Female Pelvic Med Reconstr Surg        ISSN: 2151-8378            Impact factor:   2.091


  2 in total

1.  The prevalence of microscopic hematuria in a cohort of women with pelvic organ prolapse.

Authors:  Nirmala Pillalamarri; Dara Shalom; Sharlene Sanidad; Meredith Akerman; Lawrence Lind; Harvey Winkler
Journal:  Int Urogynecol J       Date:  2014-07-01       Impact factor: 2.894

2.  Comparison of frequency of asymptomatic microhematuria in patients with stage 2-4 versus stage 0-1 pelvic organ prolapse.

Authors:  Emrah Töz; Sefa Kurt; Mehmet Tunç Canda; Çağdaş Şahin; Ibrahim Uyar
Journal:  Pak J Med Sci       Date:  2015       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.